Journal
VACCINES
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/vaccines10040549
Keywords
livedoid vasculopathy; adalimumab; anti-TNF-alpha agent
Categories
Funding
- Outstanding Youth Development Scheme of Nanfang Hospital, Southern Medical University [2018J003]
Ask authors/readers for more resources
This retrospective study describes the successful use of the anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy and provides clinical evidence of its ability to improve skin lesions and relieve pain.
Livedoid vasculopathy is a chronic, recurrent skin disorder. It seriously affects the quality of patients' life. However, the pathogenesis has not been fully identified yet. Here, this retrospective study describes the successful use of anti-TNF-alpha agent adalimumab in three cases of refractory livedoid vasculopathy, which has not been reported previously. In addition, we provide some clinical evidence that adalimumab therapy is efficient in improving skin lesions and relieving the pain of livedoid vasculopathy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available